Vorasidenib (Voranigo) for Low-Grade Glioma
The FDA has approved vorasidenib (Voranigo – Servier), an oral isocitrate dehydrogenase (IDH)inhibitor, for treatment of grade 2 astrocytoma or oligodendroglioma in patients ≥12 years old with an IDH1 or IDH2 mutation. It is the first systemic treatment to be approved in the US for this indication.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2024-10-24
- DOI
- https://doi.org/10.58347/tml.2024.1715g
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44